UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
   Smart Dalton
   126 EAST LINCOLN AVENUE
   RAHWAY, NJ 07065

2. Issuer Name and Ticker or Trading Symbol
   Merck & Co., Inc. [MRK]

3. Date of Earliest Transaction (MM/DD/YYYY)
   4/30/2024

4. If Amendment, Date Original Filed
   ____________________________

5. Relationship of Reporting Person(s) to Issuer
   (Check all applicable)
   ___ Director
   ___ 10% Owner
   ___ Officer (give title below)
   ___ Other (specify below)
   SVP Fin. - Global Controller

6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
   D

7. Nature of Indirect Beneficial Ownership (Instr. 4)
   D

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security (Instr. 3)</th>
<th>Trans. Date</th>
<th>Trans. Code</th>
<th>Amount or Price</th>
<th>Beneficial Ownership</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>5/2/2024</td>
<td>M</td>
<td>381 A $128.8</td>
<td>3,048,286 D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>5/2/2024</td>
<td>F</td>
<td>131 D $128.8</td>
<td>2,917,286 D</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Trans. Date</th>
<th>Trans. Code (Instr. 8)</th>
<th>Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>Date Exercisable and Expiration Date</th>
<th>Price of Derivative Security (Instr. 5)</th>
<th>Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted Stock Unit</td>
<td>$129.22</td>
<td>4/30/2024</td>
<td>A</td>
<td>7,031</td>
<td>4/30/2025 4/4/2027</td>
<td>7,031</td>
<td>7,031</td>
<td>D</td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td></td>
<td>4/30/2024</td>
<td>A</td>
<td>7,031</td>
<td>4/30/2025 4/29/2024</td>
<td>7,031</td>
<td>7,031</td>
<td>D</td>
</tr>
<tr>
<td>Restricted Stock Unit</td>
<td></td>
<td>5/2/2024</td>
<td>M</td>
<td>381</td>
<td>5/2/2024 5/2/2026</td>
<td>381</td>
<td>381</td>
<td>D</td>
</tr>
</tbody>
</table>

Explanation of Responses:

1. Includes .041 shares of Merck & Co., Inc. common stock not previously reported due to a clerical error.
2. Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
3. These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027.
4. The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027.
5. These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025 and 5/2/2026.
Signatures
/s/ Kelly E. W. Grez, attorney-in-fact for Dalton Smart      5/2/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.